{"groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"FG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"FG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment..","id":"FG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment..","id":"FG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"FG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"FG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 3Q4W until the end of treatment.","id":"FG007","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.8 mg/kg 3Q4W until the end of treatment.","id":"FG008","title":"Dose-escalation Part: Enapotamab Vedotin 0.8 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"FG009","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.2 mg/kg 3Q4W until the end of treatment.","id":"FG010","title":"Dose-escalation Part: Enapotamab Vedotin 1.2 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic NSCLC with classical sensitizing epidermal growth factor receptor (EGFR) mutations and/or EGFR mutations targeted by third-generation tyrosine kinase inhibitors, received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG011","title":"Expansion Part Cohort 1: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 mutation received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG012","title":"Expansion Part Cohort 3: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic melanoma with BRAF V600 wild type received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG013","title":"Expansion Part Cohort 4: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic sarcoma received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG014","title":"Expansion Part Cohort 5: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic solid tumors (excluding NSCLC, melanoma, sarcoma, and ovarian cancer unless having a known AXL gene amplification) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"FG015","title":"Expansion Part Cohort 6: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with advanced and/or metastatic platinum-resistant ovarian cancer received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG016","title":"Expansion Part Cohort 7: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or anaplastic lymphoma kinase (ALK) rearrangements received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"FG017","title":"Expansion Part Cohort 2: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.8 mg/kg 1Q3W until the end of treatment.","id":"FG018","title":"Expansion Part Cohort 2: Enapotamab Vedotin 1.8 mg/kg 1Q3W"},{"description":"Participants with advanced and/or metastatic NSCLC without activating EGFR mutations or ALK rearrangements received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"FG019","title":"Expansion Part Cohort 8: Enapotamab Vedotin 1.0 mg/kg 3Q4W"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"12"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"4"},{"groupId":"FG015","numSubjects":"5"},{"groupId":"FG016","numSubjects":"4"},{"groupId":"FG017","numSubjects":"11"},{"groupId":"FG018","numSubjects":"4"},{"groupId":"FG019","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"8"},{"groupId":"FG012","numSubjects":"9"},{"groupId":"FG013","numSubjects":"17"},{"groupId":"FG014","numSubjects":"18"},{"groupId":"FG015","numSubjects":"30"},{"groupId":"FG016","numSubjects":"17"},{"groupId":"FG017","numSubjects":"38"},{"groupId":"FG018","numSubjects":"14"},{"groupId":"FG019","numSubjects":"16"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"3"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"2"},{"groupId":"FG014","numSubjects":"2"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"3"},{"groupId":"FG018","numSubjects":"2"},{"groupId":"FG019","numSubjects":"7"}],"type":"Sponsor decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"22"},{"groupId":"FG012","numSubjects":"16"},{"groupId":"FG013","numSubjects":"25"},{"groupId":"FG014","numSubjects":"25"},{"groupId":"FG015","numSubjects":"44"},{"groupId":"FG016","numSubjects":"25"},{"groupId":"FG017","numSubjects":"55"},{"groupId":"FG018","numSubjects":"21"},{"groupId":"FG019","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"22"},{"groupId":"FG012","numSubjects":"16"},{"groupId":"FG013","numSubjects":"25"},{"groupId":"FG014","numSubjects":"25"},{"groupId":"FG015","numSubjects":"44"},{"groupId":"FG016","numSubjects":"25"},{"groupId":"FG017","numSubjects":"55"},{"groupId":"FG018","numSubjects":"21"},{"groupId":"FG019","numSubjects":"26"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}